<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245684</url>
  </required_header>
  <id_info>
    <org_study_id>ASCOVENT</org_study_id>
    <nct_id>NCT03245684</nct_id>
  </id_info>
  <brief_title>Assisted or Controlled Ventilation in Ards (Ascovent)</brief_title>
  <acronym>ASCOVENT</acronym>
  <official_title>Assessment of the Inflammatory Response Associated With the Increase of Transpulmonary Pressure in Ipoxiemic Patients During Assisted Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present pilot randomized controlled clinical trial will test the hypothesis that in&#xD;
      patients with ARDS, fixing ventilator settings to the conventional protective ventilatory&#xD;
      strategy (VT 6 ml/kg ideal body weight and Pplat ≤ 30 cmH2O, PEEP according the PEEP/FiO2&#xD;
      table), control modes of mechanical ventilation will be associated to a concentration of&#xD;
      pulmonary and systemic inflammatory mediators lower than the concentration of inflammatory&#xD;
      mediators observed during assisted modes of mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be treated according to the sedation protocols and standards of care.&#xD;
      Sedation will be guaranteed by continuous infusion of Propofol 2-4 ml / Kg / h, Remifentanil&#xD;
      0.05-0.1 mcg / Kg / min to obtain a RASS scale level of -5 of the RASS. Mio-resolution&#xD;
      eventually obtained by a loading dose of 15 mg e.v. followed by a continuous infusion of 37.5&#xD;
      mg / h of besylated Cisatracury, will be reserved for patients with P/F &lt;150.&#xD;
&#xD;
      During a 48 hrs pre-randomization period, control mechanical ventilation will be set with a&#xD;
      Tidal Volume (VT) of 6 ml / kg (for ideal weight) and a Pplat limited to 30 cm H2O;&#xD;
      inspiratory flow 50-70 l / min with end-of-breath pause of 0.2-0.5 sec, ratio I: E from 1: 1&#xD;
      to 1: 3, respiratory frequency of 20-35 steps to maintain 7.3 &lt;pH &lt;7.5. If the pH is &lt;7.30&#xD;
      the respiratory frequency will increase up to 35 / min; If the pH is&gt; 7.5, the respiratory&#xD;
      rate will be progressively reduced to the target pH range. FiO2 and The PEEP will be set&#xD;
      according to the ARDSnet table (33)&#xD;
&#xD;
      After 48 hours, the patient will be randomized through one of the following two groups:&#xD;
&#xD;
      Control Mechanical ventilation (CMV): patient's spontaneous activity will be shut done by&#xD;
      sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure&#xD;
      (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the&#xD;
      ARDSnet protocol (33).&#xD;
&#xD;
      Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and&#xD;
      sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between&#xD;
      -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the&#xD;
      pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2&#xD;
      and respiratory rate will be regulated according the ARDSnet protocol (33)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary concentration of inflammation mediators (broncho-alveolar lavage: BAL)</measure>
    <time_frame>96 hours</time_frame>
    <description>Dosage of inflammatory mediators (tumor necrosis factor-α soluble receptors, interleukin-6, interleukin-8 and interleukin-1β and interleukin-1 receptor antagonist)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic concentration of inflammation mediators (plasma)</measure>
    <time_frame>96 hours</time_frame>
    <description>The concentrations of the same mediators (tumor necrosis factor-α soluble receptors, interleukin-6, interleukin-8 and interleukin-1β and interleukin-1 receptor antagonist) in a sample of 10 ml of blood taken from a central venous line will be analyzed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of ventilator-free days (VFDs) during the 28 days immediately after randomization</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between cytokine concentration and trans-pulmonary pressure</measure>
    <time_frame>96 hours</time_frame>
    <description>End-expiratory and end-inspiratory occlusions will be performed. End-inspiratory Plateau Pressure. Pplat of the respiratory system (Pplatrs) will be the value of PAW after an end-inspiratory occlusion. End-inspiratory chest wall plateau pressure (PplatCW) will be measured as the variation in PES between end-expiratory and end-inspiratory occlusions; end-inspiratory plateau pressure of the lung (Pplatl) were estimated as Pplatrs - PplatCW</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ARDS</condition>
  <condition>Ventilator-Induced Lung Injury</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Pressure Support Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.&#xD;
assessment of inflammatory response during PSV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Mechanical Ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>assessment of inflammatory response during PSV</intervention_name>
    <description>assessment cytokines level in BAL and plasma</description>
    <arm_group_label>Controlled Mechanical Ventilation</arm_group_label>
    <arm_group_label>Pressure Support Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years of age who:&#xD;
&#xD;
               1. Are intubated less than 24 hours since meeting the Berlin definition criteria for&#xD;
                  ARDS.&#xD;
&#xD;
               2. Have a commitment to full support;&#xD;
&#xD;
               3. Have no exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intubation and mechanical ventilation (any form) for &gt; 24 hours;&#xD;
&#xD;
          2. Acute brain injury with Glasgow coma scale (GCS) &lt;7;&#xD;
&#xD;
          3. Body mass index &gt; 40;&#xD;
&#xD;
          4. Age &lt; 18 years;&#xD;
&#xD;
          5. Neuromuscular disease that impairs ability to ventilate without assistance;&#xD;
&#xD;
          6. Severe chronic respiratory disease;&#xD;
&#xD;
          7. Burns &gt; 40% total body surface area;&#xD;
&#xD;
          8. Malignancy or other irreversible disease or condition for which 6-month mortality is&#xD;
             estimated to be greater than 50%;&#xD;
&#xD;
          9. Allogeneic bone marrow transplant within the last 5 years;&#xD;
&#xD;
         10. Chronic respiratory condition making patient respirator dependent;&#xD;
&#xD;
         11. Patient, surrogate, or physician not committed to full support;&#xD;
&#xD;
         12. Acute myocardial infarction or acute coronary syndrome within 30 days;&#xD;
&#xD;
         13. Moribund patient: not expected to survive 24 hours;&#xD;
&#xD;
         14. No consent/inability to obtain consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 4, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Alessandri</investigator_full_name>
    <investigator_title>Dirigente medico I livello ( Medical Division of Anestesia andintensive care unit)</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Ventilator-induced Lung Injury</keyword>
  <keyword>cytokines</keyword>
  <keyword>mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Ventilator-Induced Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

